app-menu Social mobile

Scarica e leggi gratis su app

GenKOre Announces Collaboration with a US-based Company on In vivo Gene-editing Therapy

Gennaio 26, 2023

– SEOUL, South Korea, Jan. 26, 2023 /PRNewswire/ — GenKOre, Inc., a Korea-based biotech company with hypercompact CRISPR-Cas tools, announced that it has entered into a strategic research collaboration with a US-based biopharma company for the development of in vivo gene editing therapies. This collaboration will utilize GenKOre’s proprietary CRISPR-Cas platform, TaRGET (Tiny nuclease, augment RNA-based Genome Editing Technology). The TaRGET platform is distinct from the most popular genome editing technology, CRISPR-Cas9, in that the whole editing module can be delivered with a single AAV vector. Based on their TaRGET platform, GenKOre has developed different modalities of editing tools including TaRGET-CUT, TaRGET-Adenine Base Editing (ABE), TaRGET-AI (Gene Activation and Inhibition system). and TaRGET-FREE (Gene knock-in) . 

“This collaboration reflects the strength and potential utility of TaRGET platform in the application of in vivo gene-editing therapy”, said Yong-Sam Kim, CEO of GenKOre. “Not only will this collaboration provide an opportunity to validate the applicability of TaRGET platform to in vivo therapy, but we will also expand the utility of our technologies to a wider spectrum of rare diseases.” The collaboration was built on the mutual interest in forging transformative therapeutics for patients with rare diseases. 

Under the terms of the agreement, GenKOre will receive up to 300 million USD including an upfront, option exercise fees and milestone payments upon successful achievement of R&D and commercial milestones across two in vivo disease targets. In addition, GenKOre will receive research funding and tiered royalties up to a double-digit percentage of net sales. 

Photo – https://mma.prnewswire.com/media/1986374/GenKOre.jpg

View original content:https://www.prnewswire.co.uk/news-releases/genkore-announces-collaboration-with-a-us-based-company-on-in-vivo-gene-editing-therapy-301725691.html

Prestiti online: alcuni consigli su come scegliere

(Adnkronos) – Milano, 26 Gennaio 2023. Al giorno d’oggi sono sempre di più gli italiani che scelg…

SPINDOX, Formazione alla 24ORE Business School insieme a BPER Banca

(Adnkronos) – Gianluca Formenton (BPER) racconta il progetto realizzato con l’azienda ICT alla 24…

Dire Fare Curare il progetto di ab medica per dare voce ai pazienti, ai medici e alle loro storie di cura eccellenti

(Adnkronos) – Al Museo della Scienza di Milano una serata evento con i protagonisti dei podcast h…

JobzMall Unveils the World’s Largest Video Talent Marketplace

ORANGE COUNTY, Calif., Jan. 26, 2023 /PRNewswire/ — JobzMall, the world’s largest video talent m…

LEGGI GRATIS La Ragione

GUARDA i nostri video

ASCOLTA i nostri podcast

REGISTRATI / ACCEDI

LA RAGIONE – LE ALI DELLA LIBERTA’ SCRL
Direttore editoriale Davide Giacalone
Direttore responsabile Fulvio Giuliani
Sede legale: via Senato, 6 - 20121 Milano (MI) PI, CF e N. iscrizione al Registro Imprese di Milano: 11605210969 Numero Rea: MI-2614229

Per informazioni scrivi a info@laragione.eu

Copyright © La Ragione - leAli alla libertà

Powered by Sernicola Labs Srl